This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Oxolamine is a medication indicated in the treatment of a cough or upper respiratory tract inflammation.

Generic Name
Oxolamine
DrugBank Accession Number
DB13216
Background

Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant 1. It is listed as a prescription drug in New Zealand legislation 2. Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation 3.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 245.326
Monoisotopic: 245.152812244
Chemical Formula
C14H19N3O
Synonyms
  • Oxolamina
  • Oxolamine
  • Oxolaminum
External IDs
  • 683 M
  • AF 438

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Oxolamine citrateK5X4XBR6941949-20-8RBZIGQJSMCOHSS-UHFFFAOYSA-N
Oxolamine phosphateDMG78UE3PU131378-45-5PSCWWFOVTFSDGZ-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ASE-COLD 120 mg+50mg+1mg/5 ml PEDİATRİK ŞURUPOxolamine citrate (50 mg/5ml) + Acetaminophen (120 mg/5ml) + Chlorpheniramine maleate (1 mg/5ml)SyrupOralLİLYUM İLAÇ VE KİMYA SANAYİ TİCARET LİMİTED ŞİRKETİ2020-08-14Not applicableTurkey flag
FORZA TABLET, 30 ADETOxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine maleate (2 mg) + Phenylephrine hydrochloride (5 mg)TabletOralALİ RAİF İLAÇ SAN. A.Ş.2020-08-14Not applicableTurkey flag
KATARIN 120 MG+50 MG+1 MG/5 ML PEDIATRIK SURUP 100 MLOxolamine citrate (50 mg) + Acetaminophen (120 mg) + Chlorpheniramine maleate (1 mg)SyrupOralBİOFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
KATARİN 250 MG/100 MG/2 MG KAPSÜL, 15 ADETOxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine (2 mg)CapsuleOralBİOFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
KATARİN 250 MG/100 MG/2 MG KAPSÜL, 30 ADETOxolamine citrate (100 mg) + Acetaminophen (250 mg) + Chlorpheniramine (2 mg)CapsuleOralBİOFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
KATARIN FORT 650 MG/200 MG/60 MG/4 MG FİLM KAPLI TABLET, 20 ADETOxolamine citrate (200 mg) + Acetaminophen (650 mg) + Chlorpheniramine maleate (4 mg) + Pseudoephedrine hydrochloride (60 mg)Tablet, coatedOralBİOFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
OLEDRO HOT D TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 12 ADETOxolamine citrate (100 mg) + Acetaminophen (500 mg) + Chlorpheniramine maleate (2 mg) + Phenylephrine hydrochloride (10 mg)Granule, effervescentOralDROGSAN İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
OLEDRO HOT D TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 6 ADETOxolamine citrate (100 mg) + Acetaminophen (500 mg) + Chlorpheniramine maleate (2 mg) + Phenylephrine hydrochloride (10 mg)Granule, effervescentOralDROGSAN İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
OLEDRO HOT TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 12 ADETOxolamine citrate (100 mg) + Acetaminophen (500 mg) + Chlorpheniramine maleate (2 mg) + Phenylephrine hydrochloride (10 mg)Granule, effervescentOralDROGSAN İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
OLEDRO HOT TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 6 ADETOxolamine citrate (100 mg) + Acetaminophen (500 mg) + Chlorpheniramine maleate (2 mg) + Phenylephrine hydrochloride (10 mg)Granule, effervescentOralDROGSAN İLAÇLARI SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PERBRONS 10 MG 120 ML SURUPOxolamine (10 mg)SyrupOralCASEL ECZACI CAHİT SELİMOĞLU İLAÇ SAN. VE TİC. LTD. ŞTİ.2020-08-14Not applicableTurkey flag
PEREBRON 50MG/5 ML 120 ML SURUPOxolamine phosphate (50 mg/5ml)SyrupOralANGELİNİ İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
R05DB07 — Oxolamine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenyloxadiazoles. These are polycyclic aromatic compounds containing a benzene ring linked to a 1,2,4-oxadiazole ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Oxadiazoles
Direct Parent
Phenyloxadiazoles
Alternative Parents
Aralkylamines / Benzene and substituted derivatives / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Amine / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
90BEA145GY
CAS number
959-14-8
InChI Key
IDCHQQSVJAAUQQ-UHFFFAOYSA-N
InChI
InChI=1S/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3
IUPAC Name
diethyl[2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl]amine
SMILES
CCN(CC)CCC1=NC(=NO1)C1=CC=CC=C1

References

General References
  1. NIH - Inxight: Drugs [Link]
  2. New Zealand - Medicines Amendment Regulations 2009 [Link]
  3. Taiwan FDA - News [Link]
  4. TITCK Product Information: Fenko (oxolamine citrate) oral citrate [Link]
ChemSpider
13143
RxNav
32658
ChEBI
94607
ChEMBL
CHEMBL1620875
ZINC
ZINC000000001874
Wikipedia
Oxolamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SyrupOral
TabletOral
CapsuleOral
Tablet, coatedOral
Granule, effervescentOral
Pill
Suppository
SyrupOral
Tablet
SuppositoryRectal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.277 mg/mLALOGPS
logP2.7ALOGPS
logP3.14ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.16 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity84.15 m3·mol-1ChemAxon
Polarizability28.59 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 23, 2017 20:37 / Updated at June 05, 2021 09:13